Advantage Austria Show navigation

Austrian Zytoprotec Raises EUR 2 Mill. in Financing from Pharmaceutical Baxter Ventures

Zytoprotec
October 28, 2013

Investment initiative to invest up to USD 200 million in promising companies

Zytoprotec, a Viennese company developing dialysis solutions and other treatments based on active cytoprotection, raised 2 million EUR in financing from new investor Baxter Ventures at the beginning of 2013. Baxter Ventures is an investment initiative established by Baxter International in 2011 to invest up to USD 200 million in promising companies. As a result of the financing, Norbert Riedel, Ph.D., Baxter’s Chief Science and Innovation Officer, will join Zytoprotec’s Supervisory Board.

Read more at http://www.b3cnewswire.com/20130129832/zytoprotec-raises-eur-2-million-in-financing-from-baxter-ventures.html?goback=%2Egmp_1842476%2Egde_1842476_member_209077093#%21

print
©©ADVANTAGE AUSTRIA